2015
Pacific Edge Releases New Product Cxbladder Monitor
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB), has today released Cxbladder Monitor, its third new product in a suite of tests for the detection and management of bladder cancer. [read more]
Pacific Edge Financial Results for the Six Months Ended 30 September 2015
Pacific Edge Continues To Execute Growth Strategy in USA and Build Sales [read more]
Interim Results To Be Released On 26 November 2015
Pacific Edge Limited (NZX:PEB) intends to announce its interim results for the half year ended 30 September 2015 (HY16) on Thursday 26 November 2015, prior to 10am NZDT. [read more]
Investor Update for November 2015
Pacific Edge Limited has issued an Investor Update for November 2015. This is an informative newsletter for shareholders, to provide an update on the company’s progress. [read more]
Pacific Edge Ends Commercial Partnership with Healthscope in Australia
Following a indepth review of its progress in Australia, Pacific Edge Limited (NZX:PEB) has announced it is ending its agreement with Healthscope and looking to finalise the selection and negotiation with a new commercial partner to market and distribute its innovative Cxbladder bladder cancer diagnostic tests. [read more]
Pacific Edge Named in TIN100 Top 10 List
Pacific Edge’s global growth and positive revenue trajectory has been recognised with the cancer diagnostics company named number 5 in the TIN100 Top Ten list of Hot Emerging Companies for 2015. [read more]
Pacific Edge 2015 Annual Meeting Results
Pacific Edge held its Annual Meeting in Dunedin on 13 August 2015 with the Chairman and the CEO updating shareholders on the company’s positive performance in the financial year to date and confirming that Pacific Edge remained on track to achieve its goal of $100 million in gross revenue by its fifth full year of trading. [read more]
Pacific Edge Receives NZTE Support for Push into South East Asia
Cancer diagnostics company, Pacific Edge (NZX:PEB) has received another boost to its plans to expand its global footprint, with a three-year $600,000 grant from New Zealand Trade and Enterprise (NZTE). [read more]
Pacific Edge’s New Zealand laboratory gains CLIA approval for Cxbladder Triage test
Cancer diagnostic specialist Pacific Edge today advised it has gained regulatory approval from the USA regulatory authority CLIA (Clinical Laboratory Improvement Amendments) to enable the commercial use of its Cxbladder Triage test from its diagnostics laboratory in Dunedin. [read more]
Cxbladder User Program With Kaiser Permanente Southern California Commences Recruitment Of Patients
Pacific Edge Ltd advises that the User Program Research with Southern California Permanente Medical Group (SCPMG) to evaluate its bladder cancer technology Cxbladder within the clinical settings of Kaiser Permanente’s health care network has commenced recruitment of patients. [read more]
Tan Tock Seng Hospital User Program for Cxbladder
NZX-Listed Pacific Edge Limited has taken an important step into accessing the significant South East Asian medical market with the signing, by Pacific Edge, of a User Program agreement with one of Singapore's largest hospitals. [read more]
Pacific Edge 2 for 11 entitlement offer to raise $35.3 million
Pacific Edge Limited ("Pacific Edge" or the "Company") today announced its intention to raise $35.3 million through a fully underwritten pro-rata renounceable Rights Offer ("Offer"). [read more]
Pacific Edge Reports Good Commercial Progress In Us Market And Strong Uplift In Sales Revenue
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has announced a strong uplift in commercial revenue for the financial year ended 31 March 2015, as it continues to rollout its US sales and marketing strategy and build customer numbers. [read more]
Pacific Edge Agrees Settlement with FMA on Continuous Disclosure
Cancer diagnostic company, Pacific Edge Limited (NZX: PEB), advises that the FMA has issued it with a warning with regard to what FMA considers to be two historical breaches of its continuous disclosure obligations. [read more]
Research Shows Pacific Edge's Cxbladder Detect Outperforms Other Non-Invasive Bladder Cancer Diagnostics
Newly published research demonstrates that Cxbladder out performs other non-invasive bladder cancer diagnostics, announced Pacific Edge Ltd. [read more]
Full Year Results To Be Released On 28 May 2015
Pacific Edge Limited (NZX:PEB) intends to announce its results for the financial year ended 31 March 2015 on Thursday 28 May 2015, prior to 10am NZST. [read more]
Cxbladder Detect favourable comparison with a leading bladder cancer detection product, UroVysion FISH, to be published
Dunedin-based Pacific Edge announces a breakthrough by demonstrating its pre-eminent status as a bladder cancer diagnostic in a science paper accepted for publication by medical journal BioMed Central ("BMC") Medical Research Methodology. [read more]
Pacific Edge is successful in obtaining ISO accreditation
NZX-Listed Pacific Edge Limited today advises its Dunedin-based laboratory has been awarded ISO accreditation status, further opening up international selling opportunities. [read more]
Pacific Edge seeks additional laboratory accreditation as it pursues international opportunities
NZX-listed Pacific Edge today confirmed that it was seeking accreditation from International Accreditation New Zealand (IANZ) for its Dunedin-based diagnostics operation as it looks to pursue further international commercialisation opportunities for Cxbladder. [read more]
Cxbladder Triage paper published in international medical journal
Dunedin-based Pacific Edge said today that its research paper on Cxbladder Triage had now been published in the internationally leading medical journal BioMed Central ("BMC") Urology. [read more]
Cxbladder Triage To Be Showcased In Prestigious Medical Journal
Dunedin-based Pacific Edge will gain a global audience for one of its newest products after the internationally acclaimed medical journal BioMed Central ("BMC") Urology accepted for publication the science paper describing the clinical performance of its recently launched bladder cancer test Cxbladder Triage. [read more]
Pacific Edge Adds To Its Growing List Of Issued Patents
Specialist cancer diagnostic company Pacific Edge has been granted further international patents for two more of its cancer detection technologies. [read more]
Pacific Edge Adds India To Its Growing List Of Patents
Pacific Edge has been granted patent protection in India for its Cxbladder technology. This comes several weeks after being granted patents for 38 countries in Europe for the same technology that enables the accurate and non-invasive detection of urothelial carcinomas. [read more]
Pacific Edge Issued Patent In Europe For Gastric Cancer
Pacific Edge Limited (the Company) has extended the patent footprint for its stomach cancer technology after it was granted patent protection in Europe for "Detection of Gastric Cancer". [read more]
European Patent Office Grants Pacific Edge Patent For Cxbladder
The European Patent Office representing 38 countries in Europe has granted Pacific Edge patent protection for its Cxbladder technology that enables the accurate and non-invasive detection of urothelial carcinomas. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.